Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion
View abstract on PubMed
Summary
This summary is machine-generated.Vascular Endothelial Growth Factor C (VEGFC) signaling promotes colorectal cancer (CRC) metastasis by increasing lymphatic vessel density and compromising lymphatic barriers. Blocking VEGFR3 may prevent CRC spread.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Metastasis
Background
- Colorectal cancer (CRC) is a highly metastatic disease.
- The role of lymphangiogenesis in CRC progression is not fully understood.
- Vascular Endothelial Growth Factor C (VEGFC) signaling via VEGFR3 is implicated in lymphangiogenesis and metastasis.
Purpose Of The Study
- To investigate the role of VEGFC signaling and lymphatic barriers in colorectal cancer progression.
- To determine the impact of VEGFC and VEGFR3 on lymphangiogenesis and metastasis in CRC.
- To evaluate therapeutic strategies targeting VEGFR3 for CRC metastasis.
Main Methods
- Analysis of human colorectal tumor tissues and healthy controls using immunohistochemistry, immunoblot, and real-time PCR.
- Orthotopic implantation of CT26 CRC cells in mice, followed by treatment with anti-VEGFR3 antibody or VEGFC-encoding adenovirus.
- Evaluation of lymphatic vessel density, metastasis, and endothelial barrier integrity (CDH5 expression) in tumor tissues and relevant organs.
Main Results
- Increased levels of podoplanin, VEGFC, and VEGFR3 were observed in CRC tissues compared to controls.
- VEGFC expression led to increased lymphatic vessel density and enhanced metastasis to lymph nodes, lungs, and liver in mice.
- VEGFC compromised lymphatic endothelial barrier integrity, increasing permeability and CRC cell migration, while VEGFR3 blockade reversed these effects.
Conclusions
- VEGFC signaling through VEGFR3 promotes lymphangiogenesis and metastasis in colorectal cancer.
- VEGFC signaling reduces lymphatic endothelial barrier integrity, facilitating cancer cell spread.
- Targeting VEGFR3 presents a potential therapeutic strategy to inhibit colorectal cancer metastasis.